VIRX Stock Overview
A clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Viracta Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.017 |
| 52 Week High | US$0.89 |
| 52 Week Low | US$0.008 |
| Beta | 0.25 |
| 1 Month Change | -23.41% |
| 3 Month Change | -52.13% |
| 1 Year Change | -97.89% |
| 3 Year Change | -99.25% |
| 5 Year Change | n/a |
| Change since IPO | -99.88% |
Recent News & Updates
Shareholder Returns
| VIRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -12.7% | 1.2% | 2.2% |
| 1Y | -97.9% | -7.6% | 8.2% |
Return vs Industry: VIRX underperformed the US Biotechs industry which returned -6.9% over the past year.
Return vs Market: VIRX underperformed the US Market which returned 9.3% over the past year.
Price Volatility
| VIRX volatility | |
|---|---|
| VIRX Average Weekly Movement | 68.1% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: VIRX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: VIRX's weekly volatility has increased from 37% to 68% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 26 | Craig Jalbert | www.viracta.com |
Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company’s Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors.
Viracta Therapeutics, Inc. Fundamentals Summary
| VIRX fundamental statistics | |
|---|---|
| Market cap | US$655.78k |
| Earnings (TTM) | -US$43.29m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs VIRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIRX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$43.29m |
| Earnings | -US$43.29m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.09 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -255.6% |
How did VIRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/05 05:53 |
| End of Day Share Price | 2025/05/05 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Viracta Therapeutics, Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew Berens | Leerink Partners LLC |
| Hartaj Singh | Oppenheimer & Co. Inc. |